[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-partum-haemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-partum-haemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100635263","phase-2-role-of-intravenous-calcium-to-decrease-blood-loss-during-intrapartum-cesarean-section-100635263",false,"NCT07550413","Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section","Inclusion Criteria:\n\n* Women aged 18-45 years undergoing intrapartum cesarean section at ≥34 weeks of gestation.\n* Exposure to oxytocin during labor before CS.\n* Singleton pregnancy with no known fetal anomalies.\n\nExclusion Criteria:\n\n* Known bleeding disorders or preoperative coagulation abnormalities\n* Preeclampsia or hypertensive disorders contraindicate calcium use.\n* History of cardiac disease or arrhythmias\n* Placental abnormalities, i.e., placenta previa, accreta\n* Emergency CS with fetal distress or cord prolapse.\n* Known hypersensitivity to calcium chloride.",true,"FEMALE","18 Years","45 Years",{"count":20,"type":21},182,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To determine the effectiveness of prophylactic intravenous calcium chloride administered after cord clamping in reducing postpartum blood loss during intrapartum cesarean section.",[27,28],"Post Partum Haemorrhage","Cesarean Section Surgery",[30],"Randomized Controlled Trial","NOT_YET_RECRUITING","2026-04-19",{"date":34,"type":35},"2026-04-24","ACTUAL",{"date":37,"type":21},"2026-05",{"date":39,"type":21},"2026-12",{"name":41,"class":42},"Pak Emirates Military Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100629392","phase-3-investigating-the-efficacy-of-tranexamic-acid-as-a-prophylactic-agent-in-reducing-postpartum-hemorrhage-among-patients-undergoing-cesarean-section-in-squh-100629392","NCT07474077","Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH","PROPHYLACTIC TRANEXAMIC ACID IN REDUCING POSTPARTUM HEMORRHAGE IN CESAREAN SECTIONS","Inclusion Criteria:\n\nPregnant woman with risk factors for postpartum haemorrhage undergoing elective and emergency caesarean section in SQUH.\n\n* Previous Caesarean Section\n* Multiple pregnancy,\n* Polyhydramnios,\n* Fetal macrosomia (BW \\>4kg),\n* Anemia\n* Booking BMI\\>30\n* Previous history of postpartum hemorrhage\n* Fibroids,\n* Adenomyosis,\n* Placenta previa (non- accreta),\n* Chorioamnionitis.\n\nExclusion Criteria: Woman with conditions like\n\n* Placenta accreta spectrum,\n* Contraindications to tranexamic acid (e.g., hypersensitivity to tranexamic acid), -History of seizure disorders,\n* Kidney disease,\n* Thromboembolic disease,\n* Medical conditions or treatments associated with a high risk of thrombosis",{"count":52,"type":21},88,[54],"PHASE3","Investigating the efficacy of tranexamic acid (TXA) as a prophylactic agent in reducing postpartum haemorrhage (PPH) among patients undergoing cesarean section (CS) in SQUH: a prospective randomized controlled trial.",[27],[58,59,60,61],"Post partum haemorrhage","tranexamic acid","Caesarean section","Pregnancy","2026-03-26",{"date":64,"type":35},"2026-04-01",{"date":66,"type":21},"2026-05-01",{"date":68,"type":21},"2028-03-31",{"name":70,"class":42},"Sultan Qaboos University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100580896","outcomes-and-perceptions-of-the-implementation-of-the-jada-device-in-a-stage-ii-postpartum-hemorrhage-management-protocol-in-referral-hospitals-of-the-colombian-pacific-region-100580896","NCT06843265","Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region","Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region: a Cohort Study","JADAValle","Inclusion Criteria:\n\n* Pregnant women who are admitted to the obstetrics service scheduled for vaginal delivery in any of the participating hospitals: Fundación Valle del Lili, Hospital Universitario del Valle and Hospital Luis Ablanque de la Plata.\n* Patient admitted during the shift of one of the gynecologists trained in the use of the JADA device in the context of the research project.\n\nCriteria for the use of JADA device:\n\n* Pregnant women over or equal to 18 years of age.\n* Gestational age of pregnancy greater than 32 weeks of gestation.\n* Pregnant with vaginal delivery.\n* Pregnant with postpartum hemorrhage due to uterine atony that does not respond to treatment with uterotonics and uterine massage.\n* Postpartum hemorrhage uterine stage\u002Fstage II.\n* Vaginal delivery attended in a health institution in the context of the Hospital Padrino strategy (Fundación Valle del Lili or Hospital Universitario del Valle or Hospital Luis Ablanque de la Plata).\n\nExclusion Criteria:\n\n* Patients who, according to the attending physician's criteria, are not candidates for vaginal delivery.\n* Abnormality of the normal uterine anatomy.\n* Placental abnormalities.\n* Maternal anemia with hemoglobin less than 7 mg\u002Fdl prior to delivery.\n* Those who do not sign informed consent.",{"count":80,"type":21},24,[82],"NA","This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths. This condition presents a higher risk in low- and middle-income countries (LMICs), particularly where access to quality care is limited. Recognizing the urgency of addressing this public health problem, the Colombian Ministry of Health and Social Protection has implemented the Maternal Mortality Reduction Acceleration Plan (PARE) to improve maternal mortality indicators and meet the Sustainable Development Goals (SDGs).\n\nThe project will evaluate the results and perception of a new device in the management of stage II PPH in referral hospitals in the department of Valle del Cauca, integrated in the Hospital Padrino strategy. This initiative seeks not only to improve the understanding and treatment of PPH, but also to strengthen institutional capacities through education, creation of telecare networks and care services adapted to local needs.",[27],[86,87,88],"maternal mortality","Shock Index","care bundle","2025-02-20",{"date":91,"type":35},"2025-02-24",{"date":93,"type":21},"2025-06-01",{"date":95,"type":21},"2025-12-31",{"name":97,"class":42},"Fundacion Clinica Valle del Lili"]